Selected combination strategies aimed at inhibiting IGF-1R and related downstream pathways represent a potential strategy for future translation into novel ALL therapies, in particular when AMPK is one of the signaling proteins targeted in these combinations. This evidence concerns the gene IGF1R and acute lymphoblastic leukemia.